Inactive Instrument

Analyst Reco. Pfizer Inc. London S.E.

Equities

DA Davidson Raises Price Target on Pfizer to $35 From $30, Maintains Buy/Add Rating	20/05	MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	17/05	MT
Redburn Atlantic Adjusts Price Target on Pfizer to $27 From $26, Keeps Neutral Rating	13/05	MT
PFIZER INC : Buy rating from DZ Bank	03/05	ZD
Morgan Stanley Adjusts Price Target on Pfizer to $29 From $28	02/05	MT
Leerink Adjusts Price Target on Pfizer to $29 From $27	02/05	MT
BMO Capital Adjusts Pfizer's Price Target to $36 From $33, Keeps Outperform Rating	02/05	MT
Morgan Stanley Lifts Price Target on Pfizer to $29 From $28, Keeps Equalweight Rating	02/05	MT
PFIZER INC : Jefferies gives a Buy rating	02/05	ZD
PFIZER INC : UBS remains Neutral	01/05	ZD
PFIZER INC : JP Morgan remains Neutral	01/05	ZD
Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer	18/04	MT
Novavax Shareholder Shah Capital Pushes to Add 2 Nominees to Company's Board	15/04	MT
PFIZER INC : JP Morgan remains Neutral	12/04	ZD
Skanska Trims Scope of Work for Biomanufacturing Facility Project in US	12/04	MT
PFIZER INC : Berenberg remains Neutral	10/04	ZD
Argus Downgrades Pfizer to Hold From Buy	22/03	MT
PFIZER INC : JP Morgan sticks Neutral	07/03	ZD
PFIZER INC : JP Morgan sticks Neutral	01/03	ZD
Guggenheim Initiates Pfizer With Buy Rating, Price Target is $36	23/02	MT

No results for this search

Pfizer, Inc: A cycle for nothing?

December 14, 2023 at 09:28 pm IST

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs